Loto Biotech

Executive Summary

Loto Biotech is a Milan-based biotech startup founded in 2018 that specializes in developing siRNA-based pro-drugs for rare genetic disorders, particularly autosomal dominant diseases. The company differentiates itself through a proprietary AI-driven platform that accelerates drug discovery and reduces R&D costs. By combining siRNA technology with a pro-drug approach, Loto aims to improve target specificity and reduce off-target effects, addressing key challenges in RNA therapeutics. While still in early preclinical stages, the company has established a strong scientific foundation and is positioned to address significant unmet medical needs in rare diseases. Its focus on autosomal dominant conditions provides a clear genetic rationale for intervention, and the AI platform offers potential for efficient pipeline expansion. As a private Italian biotech, Loto Biotech is at a pre-revenue stage and has not publicly disclosed financing rounds or specific pipeline candidates. The company's success will depend on advancing lead programs through preclinical validation and securing partnerships or funding to support IND-enabling studies. The emerging RNA therapy landscape and growing interest in rare disease treatments present a favorable environment. However, the lack of disclosed data and early stage warrant cautious optimism.

Upcoming Catalysts (preview)

• H2 2026Lead Program Preclinical Proof-of-Concept Data Release50% success
• H1 2026Series A Financing Round Closing60% success
• 2026Strategic Partnership with a Larger Biopharma Company30% success